Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEvaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
Current Medical Research and Opinion, 10/02/09
Montoya A et al. – A continued improvement of symptoms is expectable until 12 weeks in treatment–naïve ADHD patients treated with atomoxetine as first–line medication. Chief limitations are the small, national sample size and the absence of data beyond the 12–week time–point.
Related Articles
Electrocardiographic Screening in Children With Attention-Deficit Hyperactivity Disorder
The American Journal of Cardiology, 10/22/09
Relevance Score: 94%
Comorbidity in Adults With Attention-Deficit Hyperactivity Disorder
Canadian Journal of Psychiatry, 10/20/09
Relevance Score: 94%
Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder
Yonsei Medical Journal, 10/29/09
Relevance Score: 93%
Adolescent Girls With Attention-Deficit/Hyperactivity and Borderline Personality Disorders
Clinical Neuropharmacology, 10/12/09
Relevance Score: 93%
Dopaminergic Haplotype as a Predictor of Spatial Inattention in Children With Attention-Deficit/Hyperactivity Disorder
Archives of General Psychiatry, 10/09/09
Relevance Score: 93%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole
Neuropsychopharmacology, 12/08/09
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
Journal of Psychopharmacology, 12/08/09
Sponsor
Article Search
Sponsor